Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer

NCT02558959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

DRUG: Irinotecan
DRUG: Capecitabine

Sponsor

Zhejiang University